<abstract xmlns="http://www.w3.org/1999/xhtml"><p> The registration of a medicinal product by EMA or FDA used to be the main driving critical success factor for the future sales of a new medicinal product. The current additional important criteria for reimbursement decisions are cost-effectiveness and budgetary impact, which are taken into consideration in order to make a value for money decision. In order to maximize the chances of obtaining reimbursement at a maximum price, it is very important to have a well thought through strategy at the early onset of the development program in order to proactively cope with the emerging reimbursement hurdles. This paper aims to provide a pricing, market access and reimbursement strategy, which is based on a strategic scan, sales forecast model, pricing model, and cost-effectiveness model. These models are interacted and linked with a discounted cash flow model in order to optimize the economic value of the company.</p></abstract>

The registration of a medicinal product by EMA or FDA used to be the main driving critical success factor for the future sales of a new medicinal product. The current additional important criteria for reimbursement decisions are cost-effectiveness and budgetary impact, which are taken into consideration in order to make a value for money decision. In order to maximize the chances of obtaining reimbursement at a maximum price, it is very important to have a well thought through strategy at the early onset of the development program in order to proactively cope with the emerging reimbursement hurdles. This paper aims to provide a pricing, market access and reimbursement strategy, which is based on a strategic scan, sales forecast model, pricing model, and cost-effectiveness model. These models are interacted and linked with a discounted cash flow model in order to optimize the economic value of the company.

Early phase value scan for biotechnology innovation

The EuroBiotech Journal

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

{"article-title":"Early phase value scan for biotechnology innovation"}

The registration of a medicinal product by EMA or FDA used to be the main driving critical success factor for the future sales of a new medicinal product. The...

Early phase value scan for biotechnology innovation

Data publikacji: 09 maj 2017

Zakres stron: 159 - 164

DOI: https://doi.org/10.24190/ISSN2564-615X/2017/02.08

© 2018

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.